The Technical Analyst
Aerie Pharmaceuticals Inc [AERI]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Aerie Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
11.47% $8.36
Last updated: 3 jul 2022 - 20:25
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 406.49 mill |
| EPS: | -1.472 |
| P/E: | 0.000 |
| Earnings Date: | Aug 02, 2022 |
| SharesOutstanding: | 48.62 mill |
| Avg Daily Volume: | 0.652 mill |
| RATING 2022-07-01 |
|---|
| B- |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Neutral | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$9.16 (9.60%) $0.803 |
| Date: 2022-07-04 |
| True Range Average |
|---|
|
+/- $0.569 ( +/- 6.81%) Range: 7.79 - 8.93 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-09 | Mchugh Julie | Buy | 16 854 | Stock Option (right to buy) |
| 2022-06-09 | Mchugh Julie | Buy | 6 245 | Common Stock |
| 2022-06-09 | Mcgraw Benjamin F Iii | Buy | 16 854 | Stock Option (right to buy) |
| 2022-06-09 | Mcgraw Benjamin F Iii | Buy | 6 245 | Common Stock |
| 2022-06-09 | Mcdonnell Peter J | Buy | 16 854 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 89.01 |
| Last 100 transactions |
| Buy: 2 092 921 | Sell: 145 950 |
Forecast:
16:00 - $8.36
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.36
Forecast 2: 16:00 - $8.36
Forecast 3: 16:00 - $8.36
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.36 (11.47% ) |
| Volume | 0.641 mill |
| Avg. Vol. | 0.652 mill |
| % of Avg. Vol | 98.32 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AERI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Jun 28 - 16:58 | sell | $7.83 | N/A | Active |
|---|
AERI
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Latest Press Releases
2022-05-25 16:30:00 - Press Release
Aerie Pharmaceuticals To Participate In The Jefferies Healthcare Conference On Friday, June 10, 2022 At 10:30 A.m. Et
Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that raj kannan, chief executive officer, along with peter lang, chief financial officer, and dr. gary sternberg, chief medical officer, will present at the jefferies healthcare conference on friday, june 10, 2022 at 10:30 a.m. eastern time in new york city, ny. date: june 10, 202
2022-05-24 07:30:00 - Press Release
Aerie Pharmaceuticals Announces First Participant Dosed In The Phase 3 Registrational Comet-2 Study Of Ar-15512 For The Treatment Of Dry Eye Disease
Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the phase 3 registrational “comet-2” study to evaluate ar-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (ded). comet-2 is the first of three trials in the phase 3 registrational program for ar-155
2022-04-26 16:05:00 - Press Release
Aerie Pharmaceuticals Announces Presentations At The Association For Research In Vision And Ophthalmology Annual Meeting In Denver, Colorado, May 1-4, 2022
Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that fourteen abstracts related to aerie's rhopressa®/netarsudil, ar-15512 in dry eye and “rock'sters” anti-inflammatory programs will be presented at the association for research in vision and ophthalmology annual meeting (arvo 2022) in denver, colorado, may 1 through 4, 2022. gary
2022-04-06 16:30:00 - Press Release
Aerie Pharmaceuticals To Participate In The 21st Annual Needham Virtual Healthcare Conference On Tuesday, April 12, 2022 At 3:00 P.m. Et
Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that raj kannan, chief executive officer, along with peter lang, chief financial officer, and dr. gary sternberg, chief medical officer, will participate in a fireside chat at the 21st annual needham virtual healthcare conference on tuesday, april 12, 2022 at 3:00 p.m. eastern time.
2022-03-18 07:00:00 - Press Release
Aerie Pharmaceuticals Appoints Peter Lang As Chief Financial Officer
Durham, n.c.--(business wire)--aerie pharmaceuticals appoints peter lang as chief financial officer
Latest News
2022-05-25 16:03:19 - Zacks Investment Research
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
2022-05-07 03:48:06 - Seeking Alpha
Aerie Pharmaceuticals' (AERI) CEO Raj Kannan on Q1 2022 Results - Earnings Call Transcript
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Hans Vitzthum – LifeSci Partners Raj Kannan – Chief Executive Officer Gary Sternberg – Chief Medical Officer Peter Lang – Chief Financial Officer Conference Call Participants Louise Chen – Cantor Serge Belanger – Needham & Company Annabel Samimy – Stifel Stacy Ku – Cowen and Company François Brisebois – Oppenheimer Carly Kenselaar – Citigroup Oren Livnat – H.C. Wainwright Operator Good afternoon.
2022-05-06 17:18:05 - Zacks Investment Research
Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
2022-05-05 19:34:35 - Zacks Investment Research
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of -1.54% and 1.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-04-11 16:33:04 - Zacks Investment Research
Aerie (AERI) Expands Market Presence Despite Stiff Competition
Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.
2022-02-27 15:16:05 - Pulse2
Aerie Pharmaceuticals (AERI) Stock: Why It Substantially Increased
The Aerie Pharmaceuticals Inc (NASDAQ: AERI) stock increased by 29.49% in the most recent trading session. This is why.
2022-02-24 21:48:05 - Seeking Alpha
Aerie Pharmaceuticals, Inc. (AERI) CEO Raj Kannan on Q4 2021 Results - Earnings Call Transcript
Aerie Pharmaceuticals, Inc. (AERI) CEO Raj Kannan on Q4 2021 Results - Earnings Call Transcript
2022-02-23 13:06:20 - Zacks Investment Research
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
2022-02-17 16:45:00 - Business Wire
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
2021-11-09 16:30:00 - Business Wire
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences. Stifel 2021 Virtual Healthcare Conference Date: T